SHX 003
Alternative Names: SHX-003Latest Information Update: 28 Dec 2022
At a glance
- Originator Shenox Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lambert-Eaton myasthenic syndrome
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Lambert-Eaton-Myasthenic-Syndrome in China (Transdermal, Patch)
- 30 Sep 2019 Shenox Pharmaceuticals intends to file for an Orphan Drug Designation status for SHX 003 (Shenox Pharmaceuticals pipeline, September 2019)
- 08 Nov 2018 Early research in Lambert-Eaton myasthenic syndrome in China (Transdermal) (Shenox Pharmaceuticals pipeline, November 2018)